[Use of beta-methyldigoxin preparations medilazine and bemecor in patients with congestive heart failure]. 1989

E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov

The two agents beta-methyldigoxin (medixin), a Soviet medilazide, and bemecor (digicor), a foreign analogue (LEK, Yugoslavia) were comparatively evaluated. An equal high (85%) clinical efficacy of the drugs was found in 81 patients with varying stages of heart failure. A positive therapeutic effect was accompanied by lower heart rate, higher diuresis and natri-and kaliuresis, decreased systolic and diastolic pressures in the pulmonary artery. The incidence of adverse reactions and the causes of their occurrence are analyzed.

UI MeSH Term Description Entries
D008297 Male Males
D008520 Medigoxin A semisynthetic digitalis glycoside with the general properties of DIGOXIN but more rapid onset of action. Its cardiotonic action is prolonged by its demethylation to DIGOXIN in the liver. It has been used in the treatment of congestive heart failure (HEART FAILURE). Metildigoxin,beta-Methyldigoxin,4'''-O-Methyldigoxin,Bemecor,Lanirapid,Lanitop,Medixin,Methyldigoxin,4''' O Methyldigoxin,beta Methyldigoxin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
April 1977, Kardiologiia,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
January 1992, European journal of clinical pharmacology,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
April 1995, Cardiovascular drugs and therapy,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
September 1975, Japanese heart journal,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
January 2003, Annals of medicine,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
October 1986, Clinical pharmacy,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
November 1953, Virginia medical monthly,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
January 1980, Japanese heart journal,
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
March 2018, Pain medicine (Malden, Mass.),
E T Razumova, and N A Volov, and P M Savenkov, and T V Grigo'reva, and E G Aleksandrova, and L V Shitikova, and L V Tatarenkova, and A M Sarkisov
September 2001, The Journal of the Arkansas Medical Society,
Copied contents to your clipboard!